TuHURA Biosciences, Inc. (HURA:NASDAQ) closed at $1.25 on November 20, 2026, down 8.09% on the day. The stock trades 63.6% below its 52-week high of $3.43 and 204.9% above its 52-week low of $0.410. Over the past year, it lost 33.9%. TuHURA Biosciences, Inc. is part of the Health Care sector.
In 252 trading sessions since November 20, 2025, HURA closed higher on 105 days (42%). Its best day was February 10, 2026 (+60.49%) and its worst was December 9, 2025 (-40.91%). The stock moved 10% or more in a single session 27 times. It opened at least 5% above the previous day's high 2 times.
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications.
Find more stocks like HURA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.